Efficacy and Safety of Oral Icotrokinra in Moderate-to-Severe Plaque Psoriasis: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis
{{output}}
Oral therapies for moderate-to-severe plaque psoriasis are limited by modest efficacy or safety concerns. Icotrokinra is a novel oral interleukin-23 receptor antagonist peptide that has shown promising efficacy in randomized trials. This study aimed to systema... ...
